As an early pioneer in long DNA synthesis, Emily is poised to accelerate the biofactory market. Prior to Twist Bioscience, she held escalating positions at Agilent Technologies where she built and led the fastest growing product line, resulting in more than $100 million in revenues and more than 300 customer publications. Dr. Leproust architected Agilent’s successful SureSelect product line which lowered the cost of sequencing and elucidated dozens of Mendelian diseases. In addition, she developed Agilent’s Oligo Library Synthesis technology where she initiated and led product and business development activities for the team as well as co-led marketing and sales efforts associated with the product line. Dr. Leproust designed and executed multiple experimental synthesis platforms to streamline manufacturing and fabrication. Prior to Agilent, she worked with Dr. X. Gau at the University of Texas developing DNA and RNA parallel synthesis processes on solid support, a project developed commercially by Xeotron Corporation. Dr. Leproust has published more than 34 peer-reviewed papers—many on synthetic DNA, and is the author of numerous patents. She earned her Ph.D. in organic chemistry from the University of Houston and her M.Sc. in industrial chemistry from the Lyon School of Industrial Chemistry in France.
“Using their insight and intelligence, Merieux Développement provides more than just critical funding for companies within their portfolio -- they guide in strategic positioning and share development and commercialization experience to help ensure the success of their portfolio companies. They anticipate future industry developments and facilitate the pathway for companies to achieve their objectives. Partnering with Merieux brings bright minds together to drive the future of healthcare.”